Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03A ADRENERGICS, INHALANTS
R03AC Selective beta-2-adrenoreceptor agonists
R03AC18 Indacaterol
D09319 Indacaterol maleate (JAN/USAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
22 Respiratory organ agents
225 Bronchodilators
2259 Others
D09319 Indacaterol maleate (JAN/USAN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01455 beta-Adrenergic receptor agonist
DG01452 beta2-Adrenergic receptor agonist
DG01057 Indacaterol
D09319 Indacaterol maleate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01057 Indacaterol
D09319 Indacaterol maleate
Transporter substrate
DG01665 ABCB1 substrate
DG01057 Indacaterol
D09319 Indacaterol maleate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRB2
D09319 Indacaterol maleate (JAN/USAN) <JP>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09319
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09319
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09319
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09319
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09319
Drug transporters
D09319
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D09319
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01455 beta-Adrenergic receptor agonist
DG01452 beta2-Adrenergic receptor agonist
DG01057 Indacaterol
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01057 Indacaterol
Transporter substrate
DG01665 ABCB1 substrate
DG01057 Indacaterol